Antibodies and antibody-derived macromolecules have established themselves as the
mainstay in protein-based therapeutic molecules (biologics). Our knowledge of the structure …

Tumor immunotherapy exerts its anti-tumor effects by stimulating and enhancing immune
responses of the body. It has become another important modality of anti-tumor therapy with …

PURPOSE Mosunetuzumab is a bispecific antibody targeting CD20 and CD3 that redirects T
cells to engage and eliminate malignant B cells and is being developed for relapsed or …

T-cell-based immunotherapies hold promise for the treatment of many types of cancer, with
three approved products for B-cell malignancies and a large pipeline of treatments in clinical …

Immuno-oncology approaches have entered clinical practice, with tremendous progress
particularly in the field of T cell-engaging therapies over the past decade. Herein, we provide …

Harnessing the power of immune cells, especially T cells, to enhance anti-tumor activities
has become a promising strategy in clinical management of hematologic malignancies. The …

Hematological toxicity is the most common adverse event after chimeric antigen receptor
(CAR) T-cell therapy. Cytopenias can be profound and long-lasting and can predispose for …

CD19-directed immunotherapies are clinically effective for treating B cell malignancies but
also cause a high incidence of neurotoxicity. A subset of patients treated with chimeric …

T-cell-engaging bispecific antibodies (BsAbs) simultaneously bind to antigens on tumour
cells and CD3 subunits on T cells. This simultaneous binding results in the recruitment of T …

Immunotherapy utilizing chimeric antigen receptor T cell (CAR-T) therapy holds promise for
hematologic malignancies, however, response rates and associated immune-related …